Drug profile

The FDA adverse-event record for Imidacolprid And Moxidectin

310 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Imidacolprid And Moxidectin. See the species affected, top reactions, and outcomes below.

310
adverse-event reports
4.8%
death-coded share
Dog
most-reported species
145
Lack of efficacy (endoparasite) - heartworm - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
310
Total Reports
15
Deaths Reported
4.8%
Death Rate

Active Ingredients

Imidacolprid And Moxidectin

Administration Routes

TopicalUnknownOral

Species Affected

Dog 289
Cat 21

Most Affected Breeds

Retriever - Labrador 72
Shepherd Dog - German 22
Terrier - Bull - American Pit 19
Domestic Shorthair 14
Crossbred Canine/dog 13
Hound (unspecified) 9
Terrier (unspecified) 9
Collie - Border 8
Beagle 8
Mixed (Dog) 6

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 145
INEFFECTIVE, HEARTWORM LARVAE 48
Lack of efficacy - NOS 30
Lethargy (see also Central nervous system depression in 'Neurological') 20
Vomiting 17
Other abnormal test result NOS 15
Anaemia NOS 9
Decreased appetite 9
Lack of efficacy (heartworm) 9
Death 8
Death by euthanasia 8
Seizure NOS 8

Outcome Breakdown

Ongoing
258 (83.2%)
Recovered/Normal
21 (6.8%)
Outcome Unknown
16 (5.2%)
Euthanized
8 (2.6%)
Died
7 (2.3%)

Imidacolprid And Moxidectin Adverse Event Insights

310 reports name Imidacolprid And Moxidectin; 15 recorded a death outcome (4.8% of reported events, not a population-level mortality rate). Active ingredient: Imidacolprid And Moxidectin. Administration routes: Topical, Unknown, Oral.

By species: Dog (289 reports), Cat (21 reports). By breed: Retriever - Labrador (72), Shepherd Dog - German (22), Terrier - Bull - American Pit (19).

Leading clinical signs: Lack of efficacy (endoparasite) - heartworm (145), INEFFECTIVE, HEARTWORM LARVAE (48), Lack of efficacy - NOS (30), Lethargy (see also Central nervous system depression in 'Neurological') (20). Outcome, 310 coded reports: Ongoing leads at 83.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.